Clinical trial · Observational
Vasculogenic Mimicry in Urothelial Carcinoma
Vasculogenic Mimicry in Urothelial Carcinoma and Its Association With Clinicopathologic Features
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators aim at: 1. Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining. 2. Correlate the presence of vasculogenic mimicry with the clinicopathologic features as age, sex, TNM stage, pathological grade, recurrence, carcinoma in situ, lymphovascular emboli, lymph node metastasis, necrosis, surgical margin, multifocality and tumor size in urothelial carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| formalin fixed paraffin embedded blocks | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- presence of recurrence of urothelial carcinoma
- interventionNames
- Other: formalin fixed paraffin embedded blocks
- label
- 2
- description
- absence of recurrence of urothelial carcinoma
- interventionNames
- Other: formalin fixed paraffin embedded blocks
Primary outcomes (1)
- measure
- Evaluate the presence of vasculogenic mimicry in urothelial carcinomas by CD31-PAS double staining
- timeFrame
- baseline
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * \- Specimens of urothelial carcinoma. Exclusion Criteria: * \- Any criteria that not fulfill the inclusion criteria such as resected urinary bladder tumors other than urothelial carcinoma.
References
Publications (2)
- BACKGROUNDZhou L, Chang Y, Xu L, Hoang ST, Liu Z, Fu Q, Lin Z, Xu J. Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. Oncotarget. 2016 Nov 15;7(46):76214-76223. doi: 10.18632/oncotarget.12775. PMID 27776348
- BACKGROUNDAso Y, Ushiyama T, Suzuki K, Tajima A, Naide Y, Ohshima S, Matsuura O, Fukushima M, Ota K, Ono Y, et al. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract]. Nihon Gan Chiryo Gakkai Shi. 1988 May 20;23(5):1046-51. No abstract available. Japanese. PMID 3418215